Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015

被引:41
作者
England, Bryant R. [1 ,2 ]
Roul, Punyasha [1 ]
Yang, Yangyuna [1 ]
Sayles, Harlan [3 ]
Yu, Fang [3 ]
Michaud, Kaleb [1 ,4 ]
Xie, Fenglong [5 ]
Curtis, Jeffrey R. [5 ]
Mikuls, Ted R. [1 ,2 ]
机构
[1] Univ Nebraska Med Ctr, Div Rheumatol & Immunol, Omaha, NE 68198 USA
[2] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA
[3] Univ Nebraska Med Ctr, Dept Biostat, Omaha, NE 68198 USA
[4] Natl Data Bank Rheumat Dis, Wichita, KS USA
[5] Univ Alabama Birmingham, Immunol & Rheumatol, Birmingham, AL USA
关键词
arthritis; epidemiology; health care; outcome assessment; rheumatoid;
D O I
10.1136/annrheumdis-2020-218282
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To compare the onset and trajectory of multimorbidity between individuals with and without rheumatoid arthritis (RA). Methods A matched, retrospective cohort study was completed in a large, US commercial insurance database (MarketScan) from 2006 to 2015. Using validated algorithms, patients with RA (overall and incident) were age-matched and sex-matched to patients without RA. Diagnostic codes for 44 preidentified chronic conditions were selected to determine the presence (>= 2 conditions) and burden (count) of multimorbidity. Cross-sectional comparisons were completed using the overall RA cohort and conditional logistic and negative binomial regression models. Trajectories of multimorbidity were assessed within the incident RA subcohort using generalised estimating equations. Results The overall cohort (n=277 782) and incident subcohort (n=61 124) were female predominant (76.5%, 74.1%) with a mean age of 55.6 years and 54.5 years, respectively. The cross-sectional prevalence (OR 2.29, 95% CI 2.25 to 2.34) and burden (ratio of conditions 1.68, 95% CI 1.66 to 1.70) of multimorbidity were significantly higher in RA than non-RA in the overall cohort. Within the incident RA cohort, patients with RA had more chronic conditions than non-RA (beta 1.13, 95% CI 1.10 to 1.17), and the rate of accruing chronic conditions was significantly higher in RA compared with non-RA (RA x follow-up year, beta 0.21, 95% CI 0.20 to 0.21, p<0.001). Results were similar when including the pre-RA period and in several sensitivity analyses. Conclusions Multimorbidity is highly prevalent in RA and progresses more rapidly in patients with RA than in patients without RA during and immediately following RA onset. Therefore, multimorbidity should be aggressively identified and targeted early in the RA disease course.
引用
收藏
页码:286 / 292
页数:7
相关论文
共 43 条
[1]  
[Anonymous], 2011, GLOB HLTH AG
[2]  
[Anonymous], 2017, HEALTH QUAL LIFE OUT, DOI DOI 10.1186/s12955-017-0649-1
[3]   Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity: Single center real life results [J].
Armagan, Berkan ;
Sari, Alper ;
Erden, Abdulsamet ;
Kilic, Levent ;
Erdat, Efe Cem ;
Kilickap, Saadettin ;
Kiraz, Sedat ;
Bilgen, Sule Apras ;
Karadag, Omer ;
Akdogan, Ali ;
Ertenli, Ihsan ;
Kalyoncu, Umut .
MEDICINE, 2018, 97 (13)
[4]   Societal cost of rheumatoid arthritis patients in the US [J].
Birnbaum, Howard ;
Pike, Crystal ;
Kaufman, Rebecca ;
Marynchenko, Maryna ;
Kidolezi, Yohanne ;
Cifaldi, Mary .
CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (01) :77-90
[5]   A systematic review of validated methods for identifying patients with rheumatoid arthritis using administrative or claims data [J].
Chung, Cecilia P. ;
Rohan, Patricia ;
Krishnaswami, Shanthi ;
McPheeters, Melissa L. .
VACCINE, 2013, 31 :K41-K61
[6]   Evaluation of a Methodologic Approach to Define an Inception Cohort of Rheumatoid Arthritis Patients Using Administrative Data [J].
Curtis, Jeffrey R. ;
Xie, Fenglong ;
Chen, Lang ;
Greenberg, Jeffrey D. ;
Zhang, Jie .
ARTHRITIS CARE & RESEARCH, 2018, 70 (10) :1541-1545
[7]   Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor a agents, a retrospective cohort study [J].
Curtis, Jeffrey R. ;
Sarsour, Khaled ;
Napalkov, Pavel ;
Costa, Laurie A. ;
Schulman, Kathy L. .
ARTHRITIS RESEARCH & THERAPY, 2015, 17
[8]   ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES [J].
DEYO, RA ;
CHERKIN, DC ;
CIOL, MA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) :613-619
[9]   Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA) [J].
Dougados, Maxime ;
Soubrier, Martin ;
Antunez, Anna ;
Balint, Peter ;
Balsa, Alejandro ;
Buch, Maya H. ;
Casado, Gustavo ;
Detert, Jacqueline ;
El-zorkany, Bassel ;
Emery, Paul ;
Hajjaj-Hassouni, Najia ;
Harigai, Masayoshi ;
Luo, Shue-Fen ;
Kurucz, Reka ;
Maciel, Gabriel ;
Martin Mola, Emilio ;
Montecucco, Carlo Maurizio ;
McInnes, Iain ;
Radner, Helga ;
Smolen, Josef S. ;
Song, Yeong-Wook ;
Vonkeman, Harald Erwin ;
Winthrop, Kevin ;
Kay, Jonathan .
ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (01) :62-68
[10]   Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications [J].
England, Bryant R. ;
Thiele, Geoffrey M. ;
Anderson, Daniel R. ;
Mikuls, Ted R. .
BMJ-BRITISH MEDICAL JOURNAL, 2018, 361